FDC Quarterly Results
FDC quarterly results. In Mar 2026, FDC (FDC) reported revenue ₹635 Cr and net profit ₹103 Cr — revenue +25.0% YoY. For annual financials, live price and key ratios, visit FDC stock price BSE.
FDC Quarterly Results — Revenue, Profit & EPS Highlights
FDC latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check FDC networth to track the company's total market size over time.
- Revenue of ₹635 Cr in Mar 2026 (-11.2% vs Jun 2026, +25.0% vs Mar 2025)
- Net Profit of ₹103 Cr in Mar 2026 (-22.6% vs Jun 2026, +164.1% vs Mar 2025)
- EBITDA of ₹156 Cr in Mar 2026 (-18.3% vs Jun 2026)
- Operating Margin of 18.0% in Mar 2026 (-3.0pp vs Jun 2026)
- Earnings Per Share of ₹6.35 in Mar 2026 (-22.0% vs Jun 2026)
FDC Quarterly Results — Revenue, EBITDA, Net Profit & EPS
FDC quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 635 | 715 | 494 | 508 | 684 | -11.2% | 25.0% |
| Net Profit (₹ Cr) | 103 | 133 | 28 | 39 | 121 | - | - |
| EBITDA (₹ Cr) | 156 | 191 | 54 | 70 | 176 | - | - |
| EPS (₹) | 6.35 | 8.14 | 1.75 | 2.38 | 7.45 | - | - |
| Operating Margin (%) | 18.0% | 21.0% | 7.0% | 11.0% | 22.0% | - | - |
FDC Share Price Trend — 1-Year Movement Across Quarterly Results
FDC 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review FDC price earnings ratio to evaluate earnings-based valuation against sector peers.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
FDC vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
FDC latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹253,522.49 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Cipla
Mar 2026 |
₹108,576.18 Cr | 1335.5 | 6,612 | 543 | -9.3% | - | 8.2% | 194.4 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores